McMaster University
Characterization of Immunothrombosis in a Murine Model of Pneumococcal Respiratory Sepsis
Abstract
dc:description.abstractSepsis is a significant global health burden, most driven by pneumococcal respiratory infections. Immunothrombosis, the interaction between innate immunity and coagulation, drives sepsis mortality, resulting in microvascular thrombosis that precipitates tissue hypoperfusion and organ failure. Despite decades of research, few advancements have been made in attempts to mitigate the host immunothrombotic response to infection. Additionally, preclinical sepsis models often lack imperative clinical characteristics, such as antibiotic therapy and supportive care. As such, we sought to develop a murine model of respiratory sepsis by the intranasal administration of Streptococcus pneumoniae. Additionally, we aimed to investigate the therapeutic potential of therapeutic-dose heparin, in its ability to improve survival in said model. C57BL/6 mice aged 11-12 weeks (both sexes) were intranasally inoculated with ~107 CFU of Streptococcus Pneumoniae P1547 (serotype 6A). For translational relevance, Ringer’s lactate and buprenorphine were administered. Additionally, the broad-spectrum cephalosporin, ceftriaxone, was introduced in a dose- and time-dependent manner. Sepsis progression was assessed via bacterial burden, organ injury and function, and immunothrombotic biomarker changes by study durations of 12, 24 and 48 hours, along with 7-day survival analysis. Finally, we incorporated treatment with the low-molecular-weight heparin, Dalteparin, at a therapeutic dose for translational relevance. Infected mice exhibited physiological signs of sepsis (Murine Sepsis Score) and did not survive beyond 7 days without antibiotic treatment. Antibiotic treatment rescued survival in a time- and dose-dependent manner. Infected mice showed pneumonia-like features, including hypoxemia and acidosis. Non-survivors displayed elevated circulating markers of inflammation (IL-6 and IL-10), complement activation (C3a) and cell-death (cell-free DNA). We observed evidence of systemic organ injury and dysfunction (elevated bilirubin), providing evidence for sepsis. Treatment with Dalteparin did not significantly improve survival outcome in this severe infection model. This model provides a platform to study sepsis mechanisms and to evaluate potential therapies.
Degree
thesis:*- Department dc:contributor.department
- Medical Sciences (Blood and Cardiovascular)
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Viksne, Jennifer
- Advisor dc:contributor.advisor
-
- Liaw, Patricia
Subjects
dc:subject × 1Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Licence dc:rights.uri
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- https://doi.org/10.71548/25376